Cwm LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 21.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,038 shares of the medical research company’s stock after selling 816 shares during the quarter. Cwm LLC’s holdings in IQVIA were worth $623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. Clear Investment Research LLC purchased a new position in shares of IQVIA in the 3rd quarter worth about $27,000. Glassy Mountain Advisors Inc. purchased a new position in shares of IQVIA in the 4th quarter worth about $31,000. Allworth Financial LP raised its position in shares of IQVIA by 36.4% in the 4th quarter. Allworth Financial LP now owns 221 shares of the medical research company’s stock worth $45,000 after purchasing an additional 59 shares during the last quarter. Trust Co. of Vermont purchased a new position in shares of IQVIA in the 3rd quarter worth about $45,000. Finally, Concord Wealth Partners purchased a new position in shares of IQVIA in the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 86.20% of the company’s stock.
Insider Activity at IQVIA
In related news, insider Kevin C. Knightly sold 4,446 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the completion of the transaction, the insider now directly owns 1,973 shares in the company, valued at approximately $445,128.53. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now directly owns 17,053 shares in the company, valued at approximately $3,922,190. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the completion of the transaction, the insider now owns 1,973 shares of the company’s stock, valued at $445,128.53. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.
IQVIA Trading Up 1.9 %
IQVIA (NYSE:IQV – Get Rating) last announced its quarterly earnings data on Friday, February 10th. The medical research company reported $2.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.76 by $0.02. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.71 billion. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.42 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 9.46 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on IQV. SVB Leerink reissued an “outperform” rating on shares of IQVIA in a research report on Friday, January 27th. Barclays decreased their target price on IQVIA from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 4th. JPMorgan Chase & Co. boosted their target price on IQVIA from $257.00 to $263.00 and gave the stock an “overweight” rating in a research report on Monday, February 27th. Credit Suisse Group reissued an “outperform” rating and issued a $265.00 target price on shares of IQVIA in a research report on Monday, February 13th. Finally, StockNews.com began coverage on IQVIA in a research report on Thursday, March 16th. They issued a “hold” rating for the company. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.50.
IQVIA Profile
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.
Recommended Stories
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- No, It Isn’t Time To Sell IBM Stock
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
